Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 5/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9103819 | 0.86 | LMNA (0.42) | MEN1MAPTKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL8761782 | 0.82 | ALDH1A1 (0.37) | MEN1MAPTKMT2AALDH1A1KDM4E | |
| SCHEMBL4568055 | 0.82 | KMT2A (0.37) | MEN1MAPTKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL4568367 | 0.81 | MEN1 (0.43) | MEN1MAPTKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL4568378 | 0.75 | ALDH1A1 (0.44) | MEN1MAPTKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL4568383 | 0.74 | ALDH1A1 (0.44) | MEN1MAPTKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL4568376 | 0.74 | MEN1 (0.43) | MEN1MAPTKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL8761774 | 0.73 | KMT2A (0.42) | MEN1MAPTKMT2ASMN1; SMN2L3MBTL1 | |
| SCHEMBL4568379 | 0.72 | ALDH1A1 (0.45) | MEN1MAPTKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL2792741 | 0.72 | ALDH1A1 (0.46) | MEN1MAPTKMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122931-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, LTB4R | MEN1 2993/4885MAPT 3199/4885KMT2A 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.